Description: Osteosarcoma (OTS) is aggressive bone malignancy without wellrecognized prognosis biomarker, predominantly occurring in children and adolescents as well as adults aged 40 years and over.Although neoadjuvant and adjuvant chemotherapy or surgical resection improves the 5- year survival rates from 20% to 70% since 1970s, the 5-year survival rate for patients with metastatic or relapsed OTS is only about 10%~30%. Informative prognostic biomarker is in need for better patient’s stratification in terms of medication strategy. TMB is defined as total number of non-synonymous somatic mutations in coding areas of per tumor genomic megabase. Numerous studies have demonstrated that tumor mutational burden (TMB) is an independent biomarker to predict clinical outcomes. However, its prognostic value in OTS remains unknown. In this study, we aim to evaluate the implication of TMB in OTS patients. .

Data type: Raw sequence reads; Exome; Variation

Sample scope: Multiisolate

Relevance: Medical

Release date: 2021-03-30

Last updated: 2021-03-30

Data size: 885.62GB